

21st Austria ATX-Prime Stocks Week 22

ATX TR			
3688.28	-1.57%	7.38%	
	Price	% week	% ytd
Addiko Bank	19.70	-1.25%	47.57%
Aluflexpack			
Agrana	13.55	0.37%	-3.90%
Amag	26.50	-0.75%	-0.75%
AT&S	21.24	-4.15%	-19.24%
Bawag	60.60	-1.54%	26.30%
stock3	17.50	0.00%	-3.31%
CA Immo	29.82	0.81%	-8.10%
DO&CO	139.80	-5.16%	4.02%
Erste Group	45.10	-4.31%	22.79%
FACC	7.06	1.29%	21.10%
Flughafen Wien	49.20	0.00%	-3.34%
Frequentis	29.40	6.14%	7.69%
Immofinanz	23.95	0.21%	13.78%
Kapsch TrafficCom	8.82	-1.34%	-1.56%
Montana Aerospace			
Marinomed Biotech	14.00	-4.44%	-52.05%
Palfinger	24.05	0.00%	-4.56%
Pierer Mobility	38.00	-0.52%	-23.54%
Porr			

Dear active investors,

ATX TR was in week 22 in correction modus and lost 1,57 percent, best stock was S Immo, for which Immofinanz plans a Squeeze Out. News came from S Immo, Immofinanz, Post, Strabag, UBM, VIG, Warimpex, S Immo, Raiffeisen Bank International and Valneva.


BSNgin weekly Spitout: The **ATX TR** down -0,19% to 8.486,22 points this week. Year-to-date the ATX TR is now at **11,43%**. Up to now there were **63** days with a positive and **43** with a negative gain. From the year-high we are **0,94%** away, from the low **15,04%**. Statistically the best weekday so far 2024 is **Friday** with 0,19%, the weakest is **Wednesday** with -0,1%.

These are the best-performers this week: **S Immo** 8,33% in front of Frequentis 6,14% and Verbund 2,43%. And the following stocks performed worst: RHI Magnesita -6,67% in front of VIG -6,2% and DO&CO -5,16%.

Further highlights this week: **Marinomed Biotech** for 8 days in a row down (14,63% loss from 16,4 to 14), also **Wienerberger** 4 days down (2,76% loss from 35,48 to 34,5), **DO&CO** 4 days down (6,17% loss from 149 to 139,8), **SBO** 4 days down (3,22% loss from 40,4 to 39,1), **RHI Magnesita** 4 days down (7,11% loss from 42,2 to 39,2).

Best-performers year-to-date as of now: S Immo 76,8% (last year: 0,16 percent) followed by Addiko Bank 47,57% (last year: 5,53 percent) and Bawag 26,3% (last year: -3,65 percent). And the worst-performing stocks year-to-date: Marinomed Biotech -52,05% (Vorjahr: -48,23 percent), followed by Pierer Mobility -23,54% (Vorjahr: -26,59 percent) and AT&S -19,24% (Vorjahr: -17,81 percent).

High above the MA200: **S Immo** 52,37%, **Addiko Bank** 33,4% and **Bawag** 22,23%. Down under the MA200: **Marinomed Biotech** -53,07%, **Pierer Mobility** -28,82% and **Semperit** -19,06%.



S Immo: In the first quarter of 2024, total income of real estate company S Immo increased from EUR 80.0m in the same period of the previous year to EUR 93.5m. This improvement was mainly due to acquisitions of higher-yielding rented properties in the Czech Republic and Austria in the previous year. The result from property valuation, which is mainly attributable to market-related valuations in Germany, totalled EUR -22.6m (Q1 2023: EUR -10.0m). Due to the increase in the result for rented properties, gross profit improved significantly from EUR 40.3m to EUR 54.2m. "The success of our strategy can be clearly seen in the key operating figures for the first quarter of 2024", comments Radka Doehring, member of the Management Board. "We have succeeded in significantly increasing rental income and gross profit is well above the previous year's level. Our strategy

14.02	-2.23%	10.39%
Österreichische Post		
30.60	-1.29%	-6.42%
Polytec Group		
3.55	-1.11%	1.28%
RBI		
16.92	-1.69%	-9.37%
RWT AG		
3.20	-8.05%	-20.00%
Semperit		
11.78	2.26%	-16.81%
S Immo		
22.10	8.33%	76.80%
Sportradar Group		
9.20	-3.16%	-7.21%
Strabag		
40.60	-0.98%	-1.93%
Telekom Austria		
8.69	0.12%	13.59%
UBM		
19.90	-1.00%	-5.69%
Uniq		
8.20	-0.61%	9.92%
Varta AG		
10.64	-3.18%	-48.72%
VAS AG		
9.00	1.12%	1.12%
Verbund		
75.80	2.43%	-9.82%
VIG		
29.50	-6.20%	11.32%
Valneva		
4.11	6.03%	-12.84%
Wienerberger		
34.50	-2.32%	14.16%
Warimpex		
0.79	-4.15%	5.50%
Zumtobel		
6.02	-0.66%	-4.14%

of intensifying our investments in higher-yielding properties is having an extremely positive impact on our earnings power - the acquisitions made in recent quarters are already making a meaningful contribution to earnings."

S Immo: weekly performance: **8.33%**

TUESDAY
28

Immofinanz: Real estate group Immobilien recorded successful operating development and generated sound growth in rental income and earnings in the first quarter of 2024. Rental income rose by 11.5% year-on-year to EUR 143.2 million. After an adjustment for new acquisitions, completions and sales, the like-for-like rental income recorded by IMMOFINANZ (excluding S IMMO) rose by a solid 6.4%. The results of asset management increased by 14.3% over the previous year to EUR 120.0 million and the results of operations improved by a strong 26.4% to EUR 104.3 million. FFO 1 after tax was 23.5% higher at EUR 69.7 million (Q1 2023: EUR 56.4 million).

Immofinanz: weekly performance: **0.21%**

Austrian Post: Austrian Post carried out the first tests of in-house delivery in 2021. The interest was enormous with more than 2,000 registrations within a very short time. Now, together with technology partner Nuki, Austrian Post is taking the next step and launching door-to-door delivery as a regular service. In the first step, Austrian Post will activate 200 users from the registrations received. If you don't have a Nuki Smart Lock yet, you will receive one free of charge. In the coming months, more users will be continuously activated for door-to-door delivery.

Österreichische Post: weekly performance: **-1.29%**

WEDNESDAY
29

Strabag: Construction group Strabag generated an output volume of € 3.4 billion in the first quarter of 2024, a slight increase of 2% compared to the same period of the previous year. The order backlog as at 31 March 2024 remained stable at a high level of € 24.6 billion year-on-year. Compared to the end of 2023, this figure grew by 5%, attributable to successful project acquisitions in the first quarter of the current year. New projects include the construction of a shipping lock in Kriegenbrunn (Germany), the expansion of a rapid transit line in Toronto (Canada) and the construction of a bridge over the river Oder near Nędza (Poland).

Strabag: weekly performance: **-0.98%**

UBM: As expected, the first quarter failed to bring a trend reversal on the real estate market, but real estate developer UBM can report on progress. UBM Development generated Total Output of €85.0m in the first quarter of 2024, compared with €53.5m in the comparative prior year period. EBT declined from €1.1m in the previous year to €-7.3m. "Our focus for the current year remains consistently on liquidity over profitability. In this respect, our first quarter performance was satisfactory," indicated UBM CEO Thomas G. Winkler. UBM expects a significant year-on-year reduction of the loss in 2024, but the protection of liquidity has priority. A return to the profit zone can be expected in 2025, most likely due to the growing supply gap as well as the steady increase in rent levels in all UBM markets. In view of the current market reorganisation, there can be

wiener boerse

CEOs & CFOs
präsentieren
Zahlen & Fakten
ihrer Unternehmen.

JETZT FILM
STARTEN 



no doubt that the remaining market participants will be able to enjoy above-average benefits.

UBM: weekly performance: -1.00%

VIG: Vienna Insurance Group (VIG) increased its gross written premiums by 11% to EUR 4.3 billion after the first quarter of 2024. With a solvency ratio of 262% as of 31 March 2024, the Group continues to be excellently capitalised. "Due to our successful broad diversification in a growth region, we remain optimistic for business development in 2024 and beyond, despite the continuing geopolitical uncertainties", says Hartwig Löger, emphasising the focus on the CEE region. With the first quarterly figures for 2024, VIG's management confirms its outlook to achieve profit before taxes within a range of EUR 825 million to EUR 875 million for the 2024 financial year.

VIG: weekly performance: -6.20%

Warimpex: Warimpex is starting off the year 2024 in a persistently challenging market environment characterised by high interest rates and elevated prices. This is reflected in a weaker profit for the first quarter compared with the same period of the prior year, moving slightly into negative territory (Q1 2024: EUR -0.8 million, Q1 2023: EUR 1.4 million). EBITDA went from EUR 5.6 million to EUR 3.8 million and EBIT from EUR 5.3 million to EUR 3.5 million. Total revenues fell by 6 per cent to EUR 12.1 million. "Despite continued challenges in the real estate industry, operational performance for Warimpex was positive overall in the first quarter with earnings before taxes of EUR 0.3 million. Our current development projects and new lettings in the office segment are proceeding according to plan," reported Warimpex CEO Franz Jurkowsch.

Warimpex: weekly performance: -4.15%

S Immo: On 28th May 2024, as part of its sales programme in Germany, real estate company S Immo has concluded contracts to sell a large portfolio consisting of 18 German commercial and one residential property with a total property transaction value of EUR 255,000,000 through separate share and asset deals. This corresponds to a discount of roughly 9.5% on the book values as of 31 December 2023, which is primarily due to the fact that this is a portfolio deal.

S Immo: weekly performance: 8.33%

THURSDAY

30

Raiffeisen Bank: Raiffeisen Bank Ukraine is issuing unsecured green loans to Ukrainian small enterprises to build solar farms and acquire electric scooters and charging stations. Individuals as well as legal entities can receive financing covering up to 80% of the cost of such equipment and its assembly, Ukrainian media reports, citing a statement on social media. Under the terms, such loans may amount to 9 million hryvni and may be granted for periods of at least 24 months at an annual interest rate of 17%-19% without any additional commissions.

RRBI: weekly performance: -1.69%

with
love
from
Vienna



Publisher: FC Chladek Drastil GmbH,
Czerninpl. 4, 1020 Wien · complete im-
print: boerse-social.com/impressum ·
editors: Christian Drastil ; Christine
Petzwinkler · bsngine:
Josef Chladek, Christian Drastil

subscription: boerse-social.com/21st

FRIDAY

31

Valneva: Valneva, a specialty vaccine company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending authorization of Valneva's single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The European Commission (EC) will review the CHMP recommendation, and a decision on the marketing authorization application of IXCHIQ® in the European Union (EU), Norway, Liechtenstein and Iceland is expected in the third quarter of 2024. If approved, it will become the first chikungunya vaccine available in Europe to address this unmet medical need. In accordance with the International Reliance Procedure (IRP), Valneva is also preparing a Marketing Authorization Application (MAA) for submission to the UK Medicines and Healthcare products Regulatory Agency (MHRA). Juan Carlos Jaramillo, Chief Medical Officer of Valneva, commented, "This positive CHMP opinion marks a crucial milestone toward introducing a preventative solution against chikungunya in the EU. In recent years, climate change has caused the Aedes mosquito, a known carrier of chikungunya and dengue viruses, to spread to areas in Europe that were previously unaffected. It is critical to provide a vaccine solution not only to European travelers going to endemic chikungunya areas, such as South America or Africa, but also to the local European populations experiencing invasive mosquito attacks. The broader we can make this vaccine accessible, the better we will mitigate the burden of this debilitating illness, and we would like to thank our partner, CEPI, for supporting us in this endeavor."

Valneva: weekly performance: 6.03%

THE NEXT 21st AUSTRIA WEEKLY WILL BE
ISSUED NEXT SATURDAY
HEAR OUR ENGLISH SPOKEN STOCK MARKET
PODCAST WITH ALLISON AND CHRIS EVERY
SUNDAY ON [CHRISTIAN-DRASTIL.COM/
PODCAST](https://christian-drastil.com/podcast)

